Search: onr:"swepub:oai:lup.lub.lu.se:55480e09-2879-42df-8bc8-1403435b9c02" >
EULAR points to con...
EULAR points to consider for conducting clinical trials in systemic lupus erythematosus
- Article/chapterEnglish2009
Publisher, publication year, extent ...
Numbers
-
LIBRIS-ID:oai:lup.lub.lu.se:55480e09-2879-42df-8bc8-1403435b9c02
-
https://lup.lub.lu.se/record/1405049URI
-
https://doi.org/10.1136/ard.2007.083022DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:118411041URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:art swepub-publicationtype
-
Subject category:ref swepub-contenttype
Notes
-
Objective: Systemic lupus erythematosus (SLE) is a complex multi-organ disease, characterised by relapses and remissions. Designing a high-quality randomised controlled trial poses many challenges. We have developed evidenced-based recommendations for points to consider in conducting clinical trials in patients with SLE. Methods: The EULAR Task Force on SLE comprised 19 specialists and a clinical epidemiologist. Initially, the evidence for clinical trial end-points in SLE was evaluated and this has been reported separately. A consensus approach was developed by the SLE Task Force in formulating recommendations for points to consider when conducting clinical trials in SLE. Results: The literature review revealed that most outcome measures used in phase 2/3 trials in SLE have not actually been validated in clinical trials, although other forms of validation have been undertaken. The final recommendations for points to consider for conducting clinical trials in SLE address the following areas: study design, eligibility criteria, outcome measures including adverse events, concomitant therapies for SLE and its complications. Conclusions: Recommendations for points to consider when conducting clinical trials in SLE were developed using an evidence-based approach followed by expert consensus. The recommendations should be disseminated, implemented and then reviewed in detail and revised using an evidence-based approach in about 5 years, by which time there will be further evidence to consider from current clinical trials.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Bertsias, G.
(author)
-
Ioannidis, J. P. A.
(author)
-
Boletis, J.
(author)
-
Bombardieri, S.
(author)
-
Cervera, R.
(author)
-
Dostal, C.
(author)
-
Font, J.
(author)
-
Gilboe, I-M
(author)
-
Houssiau, F.
(author)
-
Huizinga, T. W. J.
(author)
-
Isenberg, D.
(author)
-
Kallenberg, C. G. M.
(author)
-
Khamashta, M. A.
(author)
-
Piette, J-C
(author)
-
Schneider, M.
(author)
-
Smolen, J. S.
(author)
-
Sturfelt, GunnarLund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)reum-gst
(author)
-
Tincani, A.
(author)
-
Van Vollenhoven, R.Karolinska Institutet
(author)
-
Boumpas, D. T.
(author)
-
Reumatologi och molekylär skelettbiologiSektion III
(creator_code:org_t)
Related titles
-
In:Annals of the Rheumatic Diseases: BMJ68:4, s. 470-4761468-20600003-4967
Internet link
Find in a library
To the university's database
- By the author/editor
-
Gordon, C.
-
Bertsias, G.
-
Ioannidis, J. P. ...
-
Boletis, J.
-
Bombardieri, S.
-
Cervera, R.
-
show more...
-
Dostal, C.
-
Font, J.
-
Gilboe, I-M
-
Houssiau, F.
-
Huizinga, T. W. ...
-
Isenberg, D.
-
Kallenberg, C. G ...
-
Khamashta, M. A.
-
Piette, J-C
-
Schneider, M.
-
Smolen, J. S.
-
Sturfelt, Gunnar
-
Tincani, A.
-
Van Vollenhoven, ...
-
Boumpas, D. T.
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Rheumatology and ...
- Articles in the publication
-
Annals of the Rh ...
- By the university
-
Lund University
-
Karolinska Institutet